UBS upgrades Baloise and Helvetia to “buy” amid merger-driven cash uplift

Published 01/07/2025, 10:38
Updated 01/07/2025, 10:42
© Reuters.

Investing.com -- UBS Global Research has upgraded both Baloise Holding AG and Helvetia Holding AG to “buy,” citing a projected 20% uplift in cash generation from their proposed merger. 

HBAN, a combined entity announced on April 22 and expected to complete in Q4 2025, is expected to be the highest dividend-paying Swiss insurance company among UBS’s Swiss insurance coverage, with a 7% dividend yield.

Helvetia’s 12-month rating has been raised to “buy” from “neutral,” with its price target increased to CHF213 from CHF155. 

Baloise also received a “buy” upgrade, with its price target lifted to CHF215 from CHF190. 

UBS’s pro forma valuation of CHF213 for the combined business is underpinned by a 7.1% cost of equity and 1.2% long-term growth rate. 

For Baloise, valuation is based on an exchange ratio of 1.0119 new Helvetia shares per Baloise share.

UBS estimates CHF350 million in total cost synergies, of which CHF220 million will accrue to shareholders. 

These synergies are expected to begin contributing in FY28. No capital synergies have been modeled at this stage.

Attention ahead of the 1H25 results is likely to focus on large-loss impacts from the CHF320 million landslide in Blatten, as reported by the Swiss Insurance Association. 

Helvetia’s estimated loss is CHF30 million, while Baloise is expected to incur CHF20m in losses, similarly affecting its combined ratio by 1ppt. 

Helvetia’s Specialty business is not forecast to report material losses, and Baloise’s overall large-loss ratio is expected to remain within its typical 3–4ppt range.

Helvetia operates as a multi-line insurer focused on life, property & casualty, and reinsurance, primarily in Switzerland, with additional presence in Germany, Italy, Spain, Austria, and global reinsurance markets. 

Baloise is a composite insurer with operations across Switzerland, Belgium, Germany, and Luxembourg, with a business mix of 50% non-life, 35% life, and 15% banking & asset management.

It targets personal lines, SMEs, and industrial clients, and is aiming for a ~90% combined ratio in non-life and CHF200 million annual EBIT in life during its 2022–25 strategy cycle.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.